Lung MAP (Lung Master Protocol) is a groundbreaking clinical trial framework designed to accelerate the development of new therapies for patients with advanced non-small cell lung cancer (NSCLC). The initiative was launched in 2014 by a collaboration between the National Cancer Institute (NCI), pharmaceutical companies, and various research organizations. The goal of Lung MAP is to match patients with specific genetic mutations in their tumors to the most effective targeted therapies or immunotherapies available.
